Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study

被引：0
|
作者：
Stamatoullas, Aspasia [1 ]
Ghesquieres, Herv [2 ]
Filliatre, Lauriane Clement [3 ]
Quittet, Philippe [4 ]
Morschhauser, Franck [5 ]
Ribrag, Vincent [6 ]
Edeline, Veronique [7 ]
Brice, Pauline [8 ]
机构：
[1] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[2] Ctr Hosp Lyon Sud, Dept Hematol, Pierre Benite, France
[3] CHRU, Vandoeuvre Les Nancy, France
[4] CHU St Eloi, Dept Hematol, Montpellier, France
[5] Hop Claude Huriez, CHRU Lille, Lille, France
[6] Gustave Roussy, Villejuif, France
[7] Hop Rene Huguenin, Serv Med Nucl, Inst Curie, St Cloud, France
[8] Hop St Louis, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
132
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.
    Hatake, Kiyohiko
    Kinoshita, Tomohiro
    Fukuhara, Noriko
    Choi, Ilseung
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Maruyama, Dai
    Terui, Yasuhito
    Higuchi, Yusuke
    Onishi, Yasushi
    Abe, Yasunobu
    Kobayashi, Tsutomu
    Shirasugi, Yukari
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] THE VALUE OF BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS BASED ON POOLED-ANALYSIS
    Dada, R.
    Zekri, J.
    Bayoumy, M.
    Al Saadi, R.
    HAEMATOLOGICA, 2016, 101 : 54 - 55
  • [23] Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
    Herrera, A. F.
    Palmer, J.
    Martin, P.
    Armenian, S.
    Tsai, N-C
    Kennedy, N.
    Sahebi, F.
    Cao, T.
    Budde, L. E.
    Mei, M.
    Siddiqi, T.
    Popplewell, L.
    Rosen, S. T.
    Kwak, L. W.
    Nademanee, A.
    Forman, S. J.
    Chen, R.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 724 - 730
  • [24] Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.
    Advani, Ranjana
    Oki, Yasuhiro
    Shustov, Andrei R.
    Grove, Laurie E.
    Bartlett, Nancy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Promising Remissions in Relapsed Refractory Hodgkin Lymphoma Patients Requiring More than One Line of Salvage Chemotherapy Prior to Autologous Transplantation in the Brentuximab Vedotin Era
    Damlaj, Moussab
    Alhejazi, Ayman
    Ghazi, Samer
    Alahmari, Bader
    Alaskar, Ahmed
    Alzahrani, Mohsen
    BONE MARROW TRANSPLANTATION, 2018, 53 : 616 - 617
  • [26] Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study
    Zinzani, P. L.
    Kline, J.
    Chen, R.
    Ribrag, V.
    Salles, G.
    Matsumura, I.
    Zhu, Y.
    Ricart, A.
    Balakumaran, A.
    Fanale, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN
    Engert, A.
    Santoro, A.
    Shipp, M.
    Zinzani, P. L.
    Timmerman, J.
    Ansell, S.
    Armand, P.
    Fanale, M.
    Ratanatharathorn, V.
    Kuruvilla, J.
    Cohen, J.
    Collins, G.
    Savage, K.
    Trneny, M.
    Kato, K.
    Farsaci, B.
    Parker, S.
    Rodig, S.
    Younes, A.
    HAEMATOLOGICA, 2016, 101 : 319 - 319
  • [28] PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RANDOMIZED, PHASE 3 KEYNOTE-204 STUDY
    Fanale, M. A.
    Kline, J.
    Chen, R.
    Ribrag, V.
    Salles, G.
    Matsumura, I.
    Zhu, Y.
    Ricart, A. D.
    Balakumaran, A.
    Zinzani, P. L.
    HAEMATOLOGICA, 2016, 101 : 60 - 60
  • [29] SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY
    Walewski, J.
    Hellmann, A.
    Siritanaratkul, N.
    Ozsan, G. H.
    Ozcan, M.
    Chuncharunee, S.
    Goh, A. S.
    Jurczak, W.
    Koren, J.
    Wang, B.
    Singh, S.
    Huebner, D.
    Engert, A.
    HAEMATOLOGICA, 2016, 101 : 56 - 56
  • [30] THE IMPACT OF TREATMENT WITH BRENTUXIMAB VEDOTIN ON OVERALL SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. A NATIONWIDE POPULATION BASED ANALYSIS
    Tsirigotis, P.
    Vassilakopoulos, T.
    Mpatsis, I.
    Kaloyiannidis, P.
    Bousiou, Z.
    Gkirkas, K.
    Sakellari, I.
    Roussou, P.
    Pangalis, G.
    Moschoyianni, M.
    Vassilopoulos, G.
    Repoussis, P.
    Megalakaki, E.
    Michalis, E.
    Anagnostopoulos, N.
    Calpadaki, C.
    Papadaki, H.
    Margaritis, D.
    Kotsianidis, I.
    Hatzimichael, E.
    Briasoulis, E.
    Spyridonidis, A.
    Grentzelias, D.
    Mpanti, A.
    Anargyrou, K.
    Poulakidas, E.
    Giannoullia, P.
    Gribabi, D.
    Apostolidis, I.
    Stamouli, M.
    Konstantopoulos, K.
    Karakasis, D.
    Pappa, V.
    Panayiotidis, P.
    Harhalakis, N.
    Anagnostopoulos, A.
    Angelopoulou, M.
    HAEMATOLOGICA, 2017, 102 : 84 - 84
12345